Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.420-4.510 for the period, compared to the consensus estimate of 4.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Ratings Changes

A number of equities analysts recently issued reports on PBH shares. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Jefferies Financial Group cut their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Finally, Oppenheimer reduced their price target on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $74.75.

Prestige Consumer Healthcare Price Performance

NYSE PBH traded up $1.34 on Wednesday, reaching $51.75. 749,859 shares of the stock traded hands, compared to its average volume of 477,997. Prestige Consumer Healthcare has a 12 month low of $49.28 and a 12 month high of $89.37. The company has a market cap of $2.45 billion, a price-to-earnings ratio of 13.69, a P/E/G ratio of 1.52 and a beta of 0.40. The firm’s fifty day simple moving average is $59.12 and its 200 day simple moving average is $61.68. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, research analysts predict that Prestige Consumer Healthcare will post 4.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently made changes to their positions in PBH. UMB Bank n.a. boosted its holdings in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. Danske Bank A S acquired a new position in shares of Prestige Consumer Healthcare in the third quarter worth about $37,000. Brown Brothers Harriman & Co. purchased a new position in shares of Prestige Consumer Healthcare in the third quarter worth approximately $44,000. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Prestige Consumer Healthcare by 142.8% during the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after acquiring an additional 647 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).